Skip to main content
Download PDF

Potential molecular mechanisms and clinical implications of piRNAs in preeclampsia: a review

Reproductive Biology and Endocrinology volume 22, Article number: 73 (2024) Cite this article

Abstract

Preeclampsia is a multisystem progressive condition and is one of the most serious complications of pregnancy. Owing to its unclear pathogenesis, there are no precise and effective therapeutic targets for preeclampsia, and the only available treatment strategy is to terminate the pregnancy and eliminate the clinical symptoms. In recent years, non-coding RNAs have become a hotspot in preeclampsia research and have shown promise as effective biomarkers for the early diagnosis of preeclampsia over conventional biochemical markers. PIWI-interacting RNAs, novel small non-coding RNA that interact with PIWI proteins, are involved in the pathogenesis of various diseases at the transcriptional or post-transcriptional level. However, the mechanisms underlying the role of PIWI-interacting RNAs in the pathogenesis of preeclampsia remain unclear. In this review, we discuss the findings of existing studies on PIWI-interacting RNA biogenesis, functions, and their possible roles in preeclampsia, providing novel insights into the potential application of PIWI-interacting RNAs in the early diagnosis and clinical treatment of preeclampsia.

Background

Preeclampsia (PE) is a progressive multisystem disorder specific to pregnancy that can be divided into early-onset and late-onset phenotypes (EOPE and LOPE) based on the time of diagnosis. EOPE is commonly associated with impaired placental development and subsequent growth restriction early in pregnancy, whereas LOPE is thought to be associated with maternal endothelial dysfunction [1]. PE affects approximately 8% of pregnancies globally, with an estimated 4 million women diagnosed with PE annually, resulting in the deaths of more than 70,000 women and 500,000 fetuses and newborns [2, 3]. In the US, PE is the leading cause of maternal death, serious complications, maternal intensive care admissions, high cesarean section rates, and preterm labor. Due to scarce resources and poor access to adequate obstetric care, PE poses a more serious threat to the lives of pregnant women in low- and middle-income countries than those in high-income countries [4, 5]. However, there are currently no drugs that can prevent PE progression and the only treatment option is termination of pregnancy [4]. Therefore, there is an urgent need to develop early predictors and therapeutic targets for PE.

PIWI-interacting RNAs (piRNAs) are small non-coding RNAs with lengths ranging from 23 to 32 nt. piRNA has a 5' end uridine or tenth position adenosine preference, a 2′-O-methylation modification at the 3′ end, and is processed via a Dicer-independent mechanism from single-stranded precursor transcripts expressed in intergenic regions called piRNA clusters [6,7,8]. piRNAs, initially found to be highly expressed in germline cells, play important roles in germline development, stem cell self-renewal, transposon silencing, and gametogenesis in various organisms by forming complexes with PIWI proteins (PIWIL1, PIWIL2, PIWEL3 and PIWIL4) [9, 10]. In addition, piRNAs are also highly expressed in somatic cells and play regulatory roles, such as silencing transcriptional processes, regulating translation and mRNA stability, and interacting with several proteins [11]. The abundant regulatory mechanisms of piRNAs in germ cells and somatic cells have resulted in them gradually becoming a research hotspot, and researchers are increasingly exploring the mechanisms underlying the roles of piRNA in human disease pathogenesis and their promising applications in disease diagnosis and treatment. Recently, abnormal expression of some piRNAs and PIWI proteins have been observed to be involved in the pathogenesis of PE [12, 13]. Therefore, exploring the molecular mechanisms of piRNAs in PE may provide novel insights into the early prediction and treatment of PE. This review summarizes recent studies on piRNAs, including their biosynthesis, functions, possible epigenetic regulatory roles in the pathogenesis of PE, and their potential as biomarkers and therapeutic targets for PE.

PIWI-interacting RNAs (piRNAs)

Biogenesis of piRNAs

The motifs that give rise to piRNAs are concentrated at specific genomic loci, known as piRNA clusters [14, 15]. piRNAs can be categorized into five groups based on their origin: transposon-derived, mRNA-derived, transfer RNA (tRNA)-derived, long-stranded non-coding RNA (lncRNA)-derived, and snoRNA-derived piRNAs. Transposon-derived piRNAs originate from single-stranded clusters of transcripts, yielding both sense and antisense piRNAs. mRNA-derived piRNAs stem from the mRNA 3' untranslated region (3'UTR), such as piRNAs found in Drosophila ovarian somatic follicular cells and mouse pre-gross-lineage meiotic spermatogonia [15]. tRNA-derived piRNAs are directly produced from precursor 5'-tRNA halves (rather than mature tRNA) [16]. lncRNA-derived piRNAs, exemplified by the thick-lineage piRNAs in mouse testis, are produced from the exonic region of lncRNAs [15]. Finally, snoRNA-derived piRNAs have been observed in human CD4 primary T lymphocytes, produced through the complementary binding of pre-mRNA introns to significantly downregulate interleukin 4 (IL-4) expression, thereby inhibiting Th2 T lymphocyte development [17].

piRNAs are generated via two major pathways

To date, although the biosynthesis of piRNAs has been extensively studied in animals such as Drosophila and mice, it has not been addressed in humans. The signature of the biogenesis of piRNAs is the transcription of piRNA precursors and their subsequent processing in the cytoplasm to produce mature piRNAs, which is a unique and conserved process [18]. piRNAs clusters are transcribed into unidirectional single-stranded transcripts, which are processed into piRNA precursors by two different mechanisms depending on the origin of the piRNA clusters [8].Subsequently, piRNA precursors translocate from the nucleus to the cytoplasm, where they undergo cleavage and modifications. This generates piRNA intermediates, which then form complexes with PIWI proteins and eventually generate mature piRNAs. This process involves two main pathways: the primary processing pathway and the "ping-pong" amplification pathway [18].

Primary processing pathway

Primary processing of piRNAs is dependent on the nucleic acid endonuclease Zucchini (Zuc), located in the outer mitochondrial membrane [19, 20], which generates piRNA intermediates with a strong preference for 5'U by cleavage of the 5' end of the piRNA precursors [18]. Subsequently, the 5' end of the piRNA intermediates is added to PIWI proteins and further cleaved at the 3' end, followed by 2'-O-methylation via DmHen1/Pimetmethyl transferase to generate primary piRNAs [7, 8]. After completing primary processing, some piRNA/PIWI complexes enter the nucleus to regulate target gene transcription, inducing heterochromatin formation by directing the methylation of histone 3 lysine 9 (H3K9me3), and thus silencing transposons [21, 22]. Meanwhile, the remaining complexes are involved in the next step of processing and maturation; the "ping-pong cycle".

The "ping-pong" amplification pathway

The "ping-pong" amplification pathway, first identified in Drosophila, is the major source of piRNAs in germ cells, combining piRNA biogenesis with piRNA-dependent post-transcriptional gene silencing (PTGS). Here, Aub-piRNA and Ago3-piRNA complexes function as nucleic acid endonucleases to cleave the piRNA precursors [23,24,25]. piRNAs that bind to Aub exhibit a 5'U bias signature, whereas piRNAs that bind Ago3 have an adenine at position 10, and the two types of complexes contain complementary piRNA sequences [18]. Aub cleaves the positive-sense piRNA precursors by coupling them to a piRNA of antisense strand origin (Aub-piRNA) to generate piRNA intermediates. After processing, the newly generated piRNA (positive strand origin) is loaded onto Ago3 and acts as a slicer to cleave antisense piRNA precursors, thereby generating another piRNA (antisense strand origin), which is loaded onto Aub for subsequent rounds of amplification [26, 27].

Biological functions of piRNAs

In germ cells, piRNAs silence transposon activity and gene expression in a sequence-dependent manner to promote fertility and ensure genome integrity [28,29,30,31]. Moreover, recent evidence suggests that piRNAs are also expressed in many human tissues in a tissue-specific manner, but the extent of their expression and their roles in somatic cells remain unknown. piRNAs may also be involved in regulating the pathogenesis of various diseases (cardiovascular, neurological, respiratory, and urological diseases and various cancers) at the transcriptional or post-transcriptional level [27, 32,33,34,35,36,37].

piRNA/PIWI complex-mediated transcriptional gene silencing (TGS)

piRNA-mediated gene silencing depends on the subcellular localization of the PIWI or piRNA-induced silencing complex (piRISC). Transcription regulation is primarily carried out by PIWI proteins located in the nucleus (e.g. Drosophila PIWI and mouse MIWI2) [38]. piRNA/PIWI mediates TGS by inhibiting mRNA transcription through histone modification and de novo methylation machinery. The piRNA/PIWI complex binds to Asterix protein and enters the nucleus, where it forms a new complex after binding to Panoramix, the only known TGS-specific factor capable of inducing repression when artificially attached to chromatin or extended transcripts. Then, silencing mechanism components are recruited to initiate TGS [6, 27, 32]. First, lysine-specific demethylase 1 removes the activated histone 3 lysine 4 dimethylation (H3K4me2) marker from the promoter region, inhibiting transcription by RNA Pol II. Then, the repressive histone 3 lysine 9 trimethylation (H3K9me3) marker is recruited to the target DNA by Eggless and its cofactor Windei [27, 39]. Subsequently, heterochromatin protein 1 is recruited, leading to heterochromatin formation and transcription repression [24]. In addition, piRNAs and PIWI proteins alter transcriptional activity by regulating DNA methyltransferase (DNMT), which promotes methylation of CpG islands in the promoter region [39].

piRNA/PIWI complex-mediated post-transcriptional gene silencing (PTGS)

PTGS is carried out by the cytoplasmic piRISC through a mechanism similar to that of RNA interference (RNAi), by cleaving target mRNAs [40, 41]. For example, in Drosophila embryos, Aub directly binds to the CDS and 3′ UTR of maternal mRNAs to promote their decay in a piRNA-dependent manner [42]. The PIWI proteins involved in this event are Drosophila Aub and mouse Mili (Piwil2), both of which have nuclease endonuclease (slicer) activity similar to that of Drosophila Ago2, which cleaves RNA [38]. piR-001773 and piR-017184 have recently been shown to bind to PIWIL4 to form piRNA/PIWI complexes and promote prostate cancer (PCa) cell proliferation, migration, and invasion by mediating PCDH9 mRNA degradation through an miRNA-like mechanism in PCa cells [43]. In addition to mRNAs, piRNAs can also interact with lncRNAs [26, 44] and pseudogenes [45]. Cardiac apoptosis-associated piRNA (HAAPIR) promotes cardiomyocyte apoptosis by recruiting N-acetyltransferase 10 (NAT10) to facilitate the acetylation of TFEC mRNA and thus is a key regulator of apoptosis in cardiomyocyte cells in response to ischemia and reperfusion injury [46].

piRNA/PIWI complex-mediated protein modification

In addition to mediating TGS of target genes, the PAZ structural domain of the piRNA or PIWI proteins in piRNA/PIWI complexes can directly bind to certain proteins. piR-L-163, whose expression is downregulated in non-small cell lung cancer, plays a key role in ERM activation by directly binding to the phosphorylated ERM protein [31]. In colorectal cancer (CRC), piR-54265 specifically binds to PIWIL2 and promotes the formation of the PIWIL2/STAT3/phospho-SRC complex and phosphorylation of STAT3, thereby promoting the proliferation and metastasis of CRC cells. In this process, PIWIL2 directly recruits STAT3 through the PAZ structural domain [47].

piRNAs: potential epigenetic regulators of PE pathogenesis

The pathogenesis of PE includes inadequate remodeling of the uterine spiral arteries, inflammatory immune hyperactivation, vascular endothelial cell injury, genetic factors, and insulin resistance [48]. Impaired remodeling of the uterine spiral arteries is widely recognized as the underlying cause of PE development [49]. In the early stages of normal pregnancies, extravillous trophoblast (EVT) cells infiltrate the inner 1/3 of the myometrium and enter the lumen of small uterine spiral arterioles, gradually replacing smooth muscle cells and elastin in the vessel wall, transforming the arterioles into low-resistance high-capacity blood vessels to increase placental blood flow and ensure adequate oxygen and nutrition delivery to the fetus [50]. However, in PE, EVT cells cannot enter the lumen of small uterine spiral arterioles. In addition, EVT cells fail to invade the meconium and myometrium, and the ensuing inadequate perfusion and high velocity, turbulent blood flow originating from poorly remodeled spiral arterioles leads to placental ischemia–reperfusion injury and oxidative stress, which is the first stage in the pathogenesis of PE [4]. This process is believed to be associated with impaired smooth muscle replacement in the vascular wall of spiral arteries and atherosclerosis [51]. In the second stage, the damaged placenta releases anti-angiogenic, pro-inflammatory, and other deleterious factors into the maternal circulation, leading to activation of the inflammatory response as well as endothelial dysfunction, which ultimately causes diverse clinical manifestations [5]. This is the widely recognized two-stage theory of the pathogenesis of PE, in which epigenetic regulation mediated by non-coding RNAs plays a crucial role (Fig. 1).

Fig. 1
figure 1

Epigenetic factors in the pathogenesis of PE. Epigenetic factors including non-coding RNA, DNA methylation and histone modification trigger an impaired EVT infiltration capacity, leading to dysfunctional remodelling of the uterine spiral arteries, causing placental hypoxia–ischemia and the release of excessive anti-angiogenic factors (sFlt-1,sEng) and inflammatory factors (IL-6,TNF-α), which is the first stage in the pathogenesis of PE. Subsequently, excessive placental factors enter the maternal circulation, promoting the activation of systemic inflammatory responses and extensive frontal vascular endothelial damage, ultimately causing a reduction in the perfusion of systemic organs, which is harmful to the mother and child, which is the second stage of the pathogenesis of PE. sFlt-1:Soluble Fms-Like Tyrosine Kinase-1, sEng:solubleendoglin, EVT: extravillous trophoblast, IL-6: interleukin-6, TNF-α: tumor necrosis factor-α, PE: preeclampsia

Full size image

Role of non-coding RNA-mediated epigenetics in preeclampsia etiology

A large number of epigenetic alterations, such as altered DNA methylation, non-coding RNA regulation, and histone modifications, are present in the preeclamptic placenta and other affected tissues, which may play an important role in the progression of the disease [52]. Among them, non-coding RNAs regulate gene expression and pathogenesis. Many non-coding RNAs have been shown to be aberrantly expressed in the placentas or blood vessels of patients with PE, and they promote placental development by regulating the expression of genes associated with trophoblast cell proliferation and invasion; activating the NO-NOS pathway to regulate vascular resistance and hemodynamic changes [53]; or targeting angiogenic factors to promote angiogenesis [54]. miR-145-5p mediates trophoblast cell invasion in female patients with EOPE by regulating TNF expression [55].Zhang et al. found that lncRNA DANCR activates the PI3K/AKT pathway through downregulation of miR-214-5p expression, promoting chorionic trophoblast cell migration and invasion of chorionic trophoblasts [56]. Zhao et al. found that lncRNA FEZF1-AS1 regulates apoptosis and proliferation of placental trophoblasts by stabilizing NOC1L mRNA expression through interaction with ELAVL2 [57]. In addition, miR-574-5p and miR-1972 may act as anti-angiogenic factors that inhibit endothelial cell proliferation and migration and reduce the ability of endothelial cells to form angioid structures by downregulating the expression of the cell proliferation marker MKI67 [58]. Dysregulation of any of these regulatory non-coding RNAs may lead to the development of PE. Recent studies have shown that piRNAs have also been observed in placental tissues. Martinez et.al first described the transcriptome of piRNAs in the human placenta, they identified more than 200 piRNAs preferentially expressed in the human placenta, with a large portion of placental piRNAs being expressed from a single locus, among them, the 15 most highly expressed placental piRNAs mapped to the DLK1-DIO3 locus, all of which suggest that piRNAs may play specific roles in the placenta through complex mechanisms such as gene-specific regulation and mediation of placenta-specific epigenetic regulation [59]. Interestingly, researchers have recently identified the presence of differentially expressed piRNAs in PE placenta [12]. piRNAs that are potential causative agents in PE pathogenesis are shown in Table 1.

Table 1 piRNAs as potential causative agents in the first stage of PE pathogenesis
Full size table

Facilitators of impaired remodeling of the spiral arteries of the uterus

Impaired remodeling of uterine spiral arteries due to defective trophoblast infiltrative capacity during early embryo implantation underlies the pathogenesis of PE [48]. Abnormalities in the expression of related factors can affect the expression of signaling pathways or key factors, thereby altering the normal biological behavior of trophoblasts (Fig. 2). Using high-throughput sequencing, Lin et al. detected three piRNAs (piR-1256314, uniq_277797, uniq_271431) with upregulated expression in PE placentas, which are associated with the mTOR, apelin, autophagy, and Wingles (Wnt) signaling pathways. Further, the above piRNAs inhibit the expression of PIWIL1 protein in placental trophoblasts by regulating FXR1 and DDX6 expression, thereby negatively affecting the proliferation, migration, and invasion ability of trophoblasts and promoting apoptosis, which ultimately causes superficial placental attachment leading to the onset of PE [12]. He et al. detected differentially expressed piRNAs in PE placentas, including piR-4153, piR-8488, piR-15254, piR-16926, piR-16984, piR-20364, and piR-23338, and concluded that differentially expressed piRNAs regulate ECM formation and remodeling through miRNA-like PTGS, indirectly regulating trophoblast invasion. In addition, the activity of differentially expressed piRNAs in the pathogenesis of PE may occur via the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway [13].

Fig. 2
figure 2

Potential pathogenic factors and therapeutic targets in stage I. The piRNAs that inhibit EVT proliferation, migration and invasion or promote its apoptosis (blue) may be potential causative factors targeting the first stage of PE pathogenesis, as they may inhibit the infiltrative capacity of EVT and thus lead to impaired remodelling of the spiral arteries of the uterus, and conversely, the piRNAs that play a positive role in the generation of EVT with a normal infiltrative capacity (red) may be the therapeutic A. ~ H. indicate specific targets or pathways in which piRNAs potentially promote or inhibit the infiltrative capacity of EVT, respectively. A. p53 signaling pathway B. TGFβ signaling pathway C. STAT3 signaling pathway D. CTTN /MMPs signaling pathway E.PI3K/AKT/mTOR signaling pathway F. Wnt/β-catenin signaling pathway G. G6PD/HIF-1αsignaling pathway H. DNMT1. p21: tumor protein21, p53: tumor protein53, CDK2: cyclin dependent kinase 2, SEPW1P: selenoprotein W pseudogene 1, SEPW1: selenoprotein W, 1, TGF-β1: transforming growth factor-β1, EIF3B: eukaryotic translation initiation factor 3 subunit B, Smad2/3: SMAD family member 2/3 CTB: Cytotrophoblast cell, EMT: Epithelial-Mesenchymal Transition, α-SMA: alpha smooth muscle Actin, STAT3: signal transducer and activator of transcription 3, CTTN: cortactin, MMP2/9: matrix metallopeptidase 2/9, MT1: metallothionein 1, PI3K/AKT/mTOR: phosphatidylinositol 3 kinase/protein kinase B/mammalian target of rapamycin, S1P: SITE-1 protease, S1PRS: sphingosine-1-phosphate receptors, CDC42: cell division cycle 42, PCDH9: protocadherin 9, Wnt2B:Wnt family member 2B, G6PD: glucose-6-phosphate dehydrogenase, ROS: reactive oxygen species, HIF-1α: hypoxia inducible factor, DNMT1: DNA methyltransferase 1, PTEN: phosphatase and tensin homolog

Full size image

The PI3K/Akt signaling pathway is widely present in cells and plays an important role in cell survival, metastasis, metabolism, and angiogenesis [60,61,62]. Its dysregulation is involved in the pathogenesis of various diseases, such as osteoarthritis [63], neurological dysfunction [64, 65], diabetes [66], male infertility [67], cancer and others [68,69,70,71,72,73]. Several abnormal cellular behaviors were observed in trophoblasts following the inhibition of PI3K/Akt signaling [74,75,76,77,78,79]. Therefore, piRNAs that inhibit this pathway may disrupt the normal function of trophoblasts, thereby leading to PE. Peng et al. reported that piR-55490 inhibits the activation of the Akt/mTOR pathway in lung cancer cells by binding to the 3'UTR of mTOR mRNA and inducing its degradation, thereby inhibiting cell proliferation [80]. Another important pathway associated with PE is the p53 pathway, which is a key regulator of cell division, DNA replication, and the cell cycle [81]. p53 is activated when a cell is stressed or damaged beyond repair and inhibits cell proliferation or induces apoptosis, and it is overexpressed in the placenta and serum of patients with PE [82, 83]. As important factors in the p53 signaling pathway, non-coding RNA may act in the pathogenesis of PE through the regulation of the p53 pathway. Bao et al. reported that circ-DMNT1 regulates the JAK/STAT signaling pathway to promote trophoblast apoptosis by directly binding to the p53 protein and upregulating its expression, which arrests the cell cycle and inhibits cell invasion [81]. Alternatively, miR-495 restricts HDAC2 (an epigenetic p53 regulator) expression, activating the p53/PUMA axis, thereby inhibiting trophoblast proliferation, invasion, and migration and promoting apoptosis [84]. piRNAs have complementary binding sequences for p53, and differentially expressed piRNAs have been identified in p53 mutants [85]. As piRNAs have very similar functions and expression patterns to those of miRNAs, it is reasonable to assume that piRNAs can inhibit cell proliferation and promote apoptosis by regulating the p53 pathway, thereby promoting apoptosis and thus participating in the pathogenesis of PE. In fact, Tao et al. found that piR-MW557525 inhibited the G0/G1 phase in neuroblastoma (NB) cells by activating the p53 signaling pathway, which promoted apoptosis in NB cells [86]. Tan et al. suggested that piR-36712 has an indirect role in regulating the p53 pathway as it binds the pseudogene SEPW1P RNA and reduces the expression and stability of SEPW1P RNA. Subsequently, the expression of SEPW1, which is regulated by SEPW1P, is inhibited to further upregulate p53 expression, thereby impeding the G1 cell cycle, and ultimately reducing the proliferation, invasion, and migration of breast cancer cells [45].

In addition, there are several signal transduction pathways and related factors that regulate human trophoblast invasion/migration, such as the mitogen-activated protein kinase (MAPK) signaling pathway [87,88,89]、Wnt signaling pathway [90,91,92] and matrix metalloproteinases (MMPs) [93, 94] which are associated with the impaired remodeling of spiral arteries and are regulated by the complementary binding of piRNAs [95,96,97]. For example, piR-63049 has a 7 nt putative binding site containing for Wnt2B 3'-UTR, which negatively regulates Wnt/β-catenin pathway activity by inhibiting the expression of Wnt2B, a highly conserved member of the Wnt family, thereby inhibiting osteoclastogenesis in bone marrow stromal cells [98]. In addition, piR-19166 significantly impedes the migration of PCa cells by targeting the CTTN /MMPs pathway [99].

Facilitators of vascular damage

Excessive placental antiangiogenic factor (soluble fms-like tyrosine kinase 1, sFlt1) antagonizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), thereby inducing oxidative stress, lipid peroxidation, endothelial dysfunction, and peripheral vasoconstriction during the second phase of PE pathogenesis [100]. In normal pregnancy, maternal vascular resistance is reduced, resulting in decreased blood pressure, while in PE, these functions are disrupted due to systemic vascular disease and endothelial dysfunction, which ultimately manifests in the cardiovascular and urinary systems as hypertension and proteinuria [100]. Therefore, we propose that piRNAs associated with angiogenesis and vascular injury may act as regulators in the second stage of PE pathogenesis (Fig. 3). In a study of chronic thromboembolic pulmonary hypertension, 21 aberrant piRNAs, including piR-33151, were identified as regulatory factors of four target genes, namely, ADAMTS6, NDST1, DNM2, and SNX17, which are crucial for vascular development and promote increased vascular resistance and thus, progressive vascular remodeling, thereby elevating blood pressure [101]. This suggests that piRNAs are associated with the development of vascular tissue remodeling. In addition, piR-55490, a regulator of the mTOR pathway, promotes angiogenesis and cardiac repair and tissue regeneration, which further indicates the potential regulatory role of piRNAs in angiogenesis [102].

Fig. 3
figure 3

Potential pathogenic factors and therapeutic targets in stage II. The piRNAs that promote the enhancement of vascular resistance, inhibition of angiogenesis, induction of inflammatory response and oxidative stress (blue) may be potential pathogenic factors targeting the second stage of PE pathogenesis, and, conversely, the piRNAs that inhibit the above four processes (red) may be therapeutic targets for this stage. A. piR-823 triggers anti-angiogenic factors and Angiotensin II overproduction through overexpression of HIF-1α leading to increased vascular resistance as well as suppressed angiogenesis. B. piR-38240 and piR-34393 induce oxidative stress by generating excess ROS. C. Potential causative factors and therapeutic targets in the second phase of PE pathogenesis and their downstream targets or pathways are summarised. D. Intravesicular piR-823, piR-55490, and PIWIL4 promote VEGF secretion in different ways to induce angiogenesis. E. piR-6426 inhibits the expression of SOAT1 (Suppressor of Inflammatory Factor Release) by promoting its methylation which in turn leads to the overproduction of IL-1β and TNF-α triggering an inflammatory response, and induces oxidative stress by promoting ROS overproduction. KNPA6: karyopherinα6, CYCS: cytochrome c somatic, ADP: adenosine diphosphate, ATP: adenosine triphosphate, ROS: reactive oxygen species, Acadm: acyl‐CoA dehydrogenase, AngII: angiotensin II, HIF-1α: hypoxia inducible factor, GSTP1: glutathione s-transferase Pi 1, mTOR: mammalian target of rapamycin, VEGF: vascular endothelial growth factor, MMP9: matrix metalloproteinase-9, IL-1β:interleukin- 1β, TNF-α: tumor necrosis factor, SOAT1: sterol o-acyltransferase 1, VEGFR: vascular endothelial growth factor receptor, AKT: protein kinase B, PI3K: phosphatidylinositol 3 kinase

Full size image

Hypoxia-inducible factor (HIF), consisting of HIF-α and HIF-β subunits, is a hypoxia-activated compensatory pro-angiogenic factor [103]. HIF-α is localized in the cytoplasm and is the only oxygen-regulated subunit that determines the activity of HIF-1. HIF-1α can induce the expression of anti-angiogenic factors and inhibits the expression of pro-angiogenic factors. In addition, HIF-1α induces renin angiotensin system (RAS) expression by increasing circulating angiotensin II (AngII), leading to endothelial dysfunction and peripheral vasoconstriction, which in turn triggers PE [104]. piR-823 regulates the glucose-6-phosphate dehydrogenase (G6PD)/HIF-1α pathway by enhancing the expression of the key downstream signaling molecule G6PD, thereby inhibiting the ubiquitination of HIF-α and up-regulating the expression of HIF-α, prolonging its half-life, and reducing the intracellular ROS content to regulate the hypoxic environment [105]. Therefore, it is reasonable to assume that piR-823 triggers an increase in vascular resistance and causes vascular damage, leading to increased blood pressure by promoting the expression of HIF-α.

Increasing evidence suggests that the activation of the immune system and inflammation are key steps in vascular injury in PE [103]. Pro-inflammatory cytokines, such as IL-6, are important mediators of the maternal immune system, which are over-secreted by maternal immune cells in PE, and they activate and destroy endothelial cells by increasing vascular permeability [106]. Recent studies have shown that piR-004506 induces aberrant IL-6 mRNA expression by targeting its exonic region [107].

Oxidative stress is another important mechanism in endothelial dysfunction and vascular injury, defined as an imbalance between pro-oxidants and antioxidants. In PE, this imbalance results in extensive endothelial cell oxidative damage [108]. piR-34393 and piR-38240 inhibit the expression of cytochrome C somatic (CYCS) and KPNA6 encoding karyopherin α6, both of which are associated with cellular oxidative stress. Dysfunction of CYCS impairs mitochondrial ATP production, resulting in the generation of free radicals in mitochondria, whereas karyopherin maintains cellular homeostasis during oxidative stress [109]. Glutathione S-transferase pi 1 (GSTP1) is a protective gene that attenuates inflammatory responses, reduces cellular ROS production, and repairs oxidative damage. The PIWIL4/piR-31470 complex can cause cellular oxidative damage by methylating the promoter region of GSTP1 mRNA to modulate its expression at the epigenetic level [110].

piRNAs: potential therapeutic targets for PE

piRNAs with potential as therapeutic targets for PE are shown in Table 2.piRNAs that modulate pathways that promote trophoblast proliferation, migration, and invasion may be potential therapeutic targets for the first stage of PE pathogenesis. The PI3K/AKT signaling pathway is a target of many piRNAs, therefore these piRNAs have the potential to restore the normal function of PE placental trophoblasts through activation of the PI3K/AKT signaling pathway [80, 97].Du et al. observed that low expression of piR-31115 inhibits clear cell renal carcinoma (ccRCC) cell proliferation, invasion, and migration, and the phosphorylation levels of AKT and PI3K were significantly reduced after knockdown of piR-31115, suggesting that piR-31115 may contribute to the promotion of relevant cellular functions through activation of the PI3K/AKT pathway [111]. In addition, piR-001773 and piR-017184 can bind to PIWIL4 to form PIWI/piRNA complexes that inhibit the expression of PCDH9, an inhibitor of the PI3K/AKT pathway [43]. Furthermore, piR-004800 expression is regulated by the S1PR signaling pathway, which can prevent apoptosis by regulating the PI3K/Akt/mTOR pathway [112].

Table 2 piRNAs as potential therapeutic targets for PE
Full size table

Epithelial-mesenchymal transition (EMT) is a key mechanism for the differentiation of human cytotrophoblasts (CTBs) into EVTs, and disruption of this mechanism leads to the generation of EVTs with insufficient invasive capacity to complete EMT to effectively achieve maternal spiral artery remodeling, which in turn triggers PE [113]. The TGF-β pathway regulates EMT and is modulated by piRNAs [114]. For example, piR-25783 activates the TGF-β/Smad2/Smad3 pathway in fibroblasts by increasing Smad2 and Smad3 phosphorylation, promoting the fibroblast-to-myofibroblast transition (FMT) process and enhancing the proliferative and metastatic properties of tumor cells [115]. In addition, piR-823 up-regulates TGF-β1 expression at the post-translational level by binding to EIF3B protein [116]. Furthermore, piR-32364 may potentially regulate the TGF-β pathway [117].

In addition, piRNAs that activate the Wnt signaling pathway are also potential therapeutic targets. piR-823 indirectly activates the Wnt signaling pathway by methylating the adenomatous polyposis coli (APC) promoter and promotes cell proliferation, migration, and invasion [118]. In addition, piR-823 inhibits ubiquitination of HIF-6α by up-regulating glucose-1-phosphate dehydrogenase (G1PD) expression and ultimately up-regulates glucose consumption and inhibits intracellular ROS levels in cancer cells. Thus, piR-823 may promote proliferation, invasion, and anti-apoptosis of CRC cells by regulating the G6PD/HIF-1α pathway [105]. PiR-39980 promotes migration and invasion of the human osteosarcoma cell line HOS by facilitating MMP-2 activation [119]. piR-54265 binds to the PIWIL2 protein to form the PIWIL2/STAT3/phosphorylated-SRC (p-SRC) complex, which activates STAT3 signaling and promotes proliferation and metastasis in CRC cells [47].

In the second stage of PE pathogenesis, placental factors enter the maternal circulation and promote vascular endothelial cell injury, activating the systemic inflammatory response and resulting in clinical manifestations such as hypertension and proteinuria. Thus, we believe that piRNAs that promote angiogenesis or play roles in vascular injury restoration are promising therapeutic targets for PE. The VEGF family play crucial roles in the complex and coordinated vascular and angiogenic processes under physiological and pathological conditions. VEGF is known for its endothelial vasodilatory effects mediated through NO formation and prostacyclin release, and defects in this signaling pathway during PE result in endothelial dysfunction, proteinuria, and hypertension [120]. The existence of binding sites for piRNAs on VEGF and their possible regulation of the VEGF pathway are suggestive of the role of piRNAs in regulating the pathogenesis of diseases associated with angiogenesis disorder. piR-823 in extracellular vesicles translocates to the endothelium to promote the secretion of VEGF, thus enhancing angiogenic activity [121]. Since many piRNAs need to bind to PIWI proteins to form complexes in order to fulfil their biological functions, the possible role of PIWI proteins in neovascularization should not be overlooked. VEGF binds to the VEGF receptor (VEGFR) and activates the VEGFR tyrosine kinase, which promotes endothelial cell proliferation, migration, and tube formation. Knockdown of PIWIL4 inhibits VEGF secretion and inhibits the phosphorylation of VEGFR2, which in turn inhibits angiogenesis [122]. This regulatory role has been confirmed in studies of diabetic retinopathy (DR). In addition, PIWIL4 has been shown to regulate the expression of MMP 9, which is important for neoangiogenesis [123, 124]. Hong et al. found that piR-6426 inhibits the secretion of inflammatory factors (IL-1βand TNF-α) as well as the production of ROS. In addition, piR-6426 promotes SOAT1 (which promotes the release of inflammatory factors) methylation by recruiting DNA-methyltransferase 3B (DNMT3B) to ameliorate oxidative stress-induced dysfunction in damaged cells [125].Knockdown of glutathione peroxidase 5 (GPX5), a sperm oxidative damage protector, resulted in a significant decrease in the expression of piRNAs (piR-125360, piR-14721, piR-17753, and piR-20751) that bind to PIWIL1/PIWIL2. The mRNA levels of their target genes were up-regulated, most of which were oxidative stress-related genes [126]. This suggests that these piRNAs degrade the mRNA of oxidative stress response genes, thereby reducing oxidative damage by binding to PIWIL1/PIWIL2 to form a silencing complex.

piRNAs: peripheral blood biomarkers for early prediction of PE

Abnormal expression of piRNA influences the pathogenesis of PE, exemplifying the their potential as valuable diagnostic biomarkers. Researchers have demonstrated the differential expression of piRNAs in the placentas of patients with PE [12, 13], however, the level of piRNAs in PE serum, which is more easily sampled, efficiently monitored, and longitudinally assessed for therapeutic dynamics, has not been studied. piRNAs can readily cross cell membranes into the circulation, and are stable in blood and resistant to degradation by ribonucleases in bodily fluids. In addition, their levels can be easily and reliably measured by quantitative real-time polymerase chain reaction; therefore, they can be used for routine processing of clinical samples [39, 127].

Mai et al. assayed serum piR-54265 levels under different storage conditions, including immediate detection by fresh extraction, incubation at 37 °C for 24 h, maintenance at room temperature for 72 h, and repeated freezing and thawing, and no significant changes were detected [128]. This provides strong evidence that piRNAs are stable in serum. Gál et al. Identified piR-016658 as an early biomarker of preterm PE from plasma exosomes samples of pregnant women in early pregnancy by the next generation sequencing and qPCR [129]. However, the small sample size is a noteworthy issue and further validation in more patients is still needed. In addition, the investigators pointed out that due to the limitations of blood sample size and difficulty of exosome extraction, directly obtaining piR-016658 from blood samples or other body fluids may be more appropriate. However, piRNA as a noninvasive biomarker of PE has been little studied in peripheral blood. Nevertheless, piRNAs have been extensively studied as serum tumor biomarkers. For example, piR-823 is the standard biomarker for screening circulating tumor cells (CTCs) in gastric cancer, positively correlates with T stage and distant metastasis, and has a higher positive detection rate compared with that of conventional markers such as serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19–9 (CA19-9) [39]. An increased risk of lymph node metastasis was associated with higher levels of piR-823, and piR-823 showed high specificity (AUC = 0.713) for detecting esophageal squamous cell carcinoma (ESCC), suggesting its potential as a diagnostic and prognostic biomarker. In addition, piR-13643 and piR-21238 expression correlates with the clinical stages of papillary thyroid carcinoma (PTC), and they show better specificity than the current biomarker, HBME1, in differentiating between benign and malignant nodules [130]. Additionally, two piRNAs have been found to represent the molecular signature related to hypertension-associated urinary albumin excretion (UAE). piR-32157 expression is up-regulated in the urinary and plasma exosomes of hypertensive patients and down-regulated in plasma. piRNA-33056 expression was up-regulated in plasma exosomes and plasma but down-regulated in the urinary exosomes of patients with UAE [131].

Collectively, these findings reflect the great potential of piRNAs as diagnostic biomarkers. However, the relatively low expression levels of piRNAs in bodily fluids compared with those of other small RNAs, such as miRNAs, may hinder their detection and analysis. In addition, since EOPE and LOPE have different pathogenesis and the role piRNAs play in the pathogenesis of PE may be related to their expression levels, there may be significant differences in the expression of piRNAs in the placenta and maternal circulation of different subtypes of PE. This emphasizes that the homogeneity of the patient population should be emphasized in the study of piRNAs as noninvasive biomarkers of PE. Therefore, the application of piRNAs as non-invasive biomarkers for diagnosing diseases remains difficult.

Conclusions and perspectives

In this review, by summarizing the piRNAs that regulate PI3K/Akt/mTOR, p53 signaling pathway, MAPK and other signaling pathways that may play a promotional or inhibitory role in uterine helical artery remodeling disorders、vascular endothelial cell damage and activation of inflammatory response, we thoroughly studied the functions of piRNAs and their regulatory mechanisms on PE pathogenesis, and searched for stable early screening molecular markers and new diagnostic and therapeutic targets in peripheral blood of patients with PE, which are of great significance for the early diagnosis and treatment of PE. To the best of our knowledge, this is the first review describing the possible roles of piRNAs in PE pathogenesis and as early diagnostic factors and therapeutic targets for PE.

However, as mentioned above, the same piRNAs may play opposite roles in the pathogenesis of PE, such as piR-823. Therefore, more studies are needed to investigate the specific mechanisms by which piRNAs play a role in PE pathogenesis. For example, in vitro and in vivo functional assays should be performed to investigate at what level piRNAs interact with target genes or pathways.

Currently, with the development of next-generation sequencing and other advanced detection technologies, as well as the stability of piRNAs in peripheral blood, detecting aberrant expression of piRNAs in the peripheral blood of PE patients has become possible. However, the reliability of using piRNAs for PE diagnosis remains unclear. There have been no studies on the expression levels of piRNAs in PE peripheral blood, and whether they differ from that of healthy pregnant women remains unknown. Although piRNAs are differentially expressed in PE, a defined threshold for piRNA expression levels in PE and physiological blood pressure elevation during pregnancy is required. In addition, whether piRNAs are expressed at different levels at different stages of pregnancy also requires investigation. Finally, the higher cost of detecting and identifying piRNAs in tissues or bodily fluids compared with that of existing assays limits the widespread use of piRNAs as biomarkers.

Based on the summary of the existing findings, our next priority is to investigate whether differentially expressed piRNAs are present in the peripheral blood of patients with PE, whether they are PE-specific, and whether their activity is interfered with by other pathological or physiological factors. In addition, the differences in piRNA expression between PE and normal pregnancy will be further investigated to determine the optimal gestational week for early prediction of PE. After completion of the above work, in vitro experiments will be conducted to investigate the roles of differentially expressed piRNAs in trophoblasts and vascular endothelial cells to determine the specific mechanisms involved in the pathogenesis of PE, which will ensure the rationality and scientific validity of the use of piRNAs as biomarkers of PE in peripheral blood and lay the foundation for the application of piRNAs as therapeutic targets for the early treatment of PE. Overall, we hope that the advances described in this review will stimulate further research on piRNAs as non-invasive early predictors and therapeutic targets for PE.

Availability of data and materials

No datasets were generated or analysed during the current study.

Abbreviations

PE:

Preeclampsia

piRNA:

PIWI-interacting RNA

tRNA:

Transfer RNA

lncRNA:

Long-stranded non-coding RNA

3'UTR:

3' Untranslated region

IL-4:

Interleukin 4

Zuc:

Zucchini

H3K9me3:

Histone 3 lysine 9

PTGS:

Post-transcriptional gene silencing

piRISC:

PIWI or piRNA-induced silencing complex

H3K4me2:

Histone 3 lysine 4 dimethylation

DNMT:

DNA methyltransferase

PCa:

Promote prostate cancer

CRC:

Colorectal cancer

EVT:

Extravillous trophoblast

Wnt:

Wingles

PI3K/AKT/mTOR:

Phosphatidylinositol 3 kinase/protein kinase B/mammalian target of rapamycin

NB:

Neuroblastoma

MAPK:

Mitogen-activated protein kinase (

VEGF:

Vascular endothelial growth factor

HIF:

Hypoxia-inducible factor

AngII:

Angiotensin II

sFlt-1:

Soluble Fms-Like Tyrosine Kinase-1

sEng:

Solubleendoglin

IL-6:

Interleukin-6

TNF-α:

Tumor necrosis factor-α

p21:

Tumor protein21

p53:

Tumor protein53

CDK2:

Cyclin dependent kinase 2

SEPW1P:

Selenoprotein W pseudogene 1

TGF-β1:

Transforming growth factor-β1

EIF3B:

Eukaryotic translation initiation factor 3 subunit B

Smad2/3:

SMAD family member 2/3

CTB:

Cytotrophoblast cell

EMT:

Epithelial-Mesenchymal Transition

α-SMA:

Alpha smooth muscle Actin

STAT3:

Signal transducer and activator of transcription 3

CTTN:

Cortactin

MMP2/9:

Matrix metallopeptidase 2/9

MT1:

Metallothionein 1, S1P: SITE-1 protease, S1PRS: sphingosine-1-phosphate receptors

CDC42:

Cell division cycle 42

PCDH9:

Protocadherin 9

G6PD:

Glucose-6-phosphate dehydrogenase

ROS:

Reactive oxygen species

HIF-1α:

Hypoxia inducible factor

PTEN:

Phosphatase and tensin homolog

KNPA6:

Karyopherinα6

CYCS:

Cytochrome c somatic

ADP:

Adenosine diphosphate

ATP:

Adenosine triphosphate

Acadm:

Acyl‐CoA dehydrogenas

References

  1. Aneman I, Pienaar D, Suvakov S, Simic TP, Garovic VD, McClements L. Mechanisms of key innate immune cells in early- and late-onset preeclampsia. Front Immunol. 2020;11:1864.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Docheva N, Arenas G, Nieman KM, Lopes-Perdigao J, Yeo KJ, Rana S. Angiogenic biomarkers for risk stratification in women with preeclampsia. Clin Chem. 2022;68(6):771–81.

    Article  PubMed  Google Scholar 

  3. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The international Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145 Suppl 1(Suppl 1):1–33.

    Article  PubMed  Google Scholar 

  4. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet. 2021;398(10297):341–54.

    Article  CAS  PubMed  Google Scholar 

  5. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–112.

    Article  CAS  PubMed  Google Scholar 

  6. Czech B, Munafò M, Ciabrelli F, Eastwood EL, Fabry MH, Kneuss E, et al. piRNA-guided genome defense: from biogenesis to silencing. Annu Rev Genet. 2018;52:131–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Iwasaki YW, Siomi MC, Siomi H. PIWI-interacting RNA: its biogenesis and functions. Annu Rev Biochem. 2015;84:405–33.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang J, Chen S, Liu K. Structural insights into piRNA biogenesis. Biochim Biophys Acta Gene Regul Mech. 2022;1865(2):194799.

    Article  CAS  PubMed  Google Scholar 

  9. Shi S, Yang ZZ, Liu S, Yang F, Lin H. PIWIL1 promotes gastric cancer via a piRNA-independent mechanism. Proc Natl Acad Sci U S A. 2020;117(36):22390–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ozata DM, Gainetdinov I, Zoch A, O’Carroll D, Zamore PD. PIWI-interacting RNAs: small RNAs with big functions. Nat Rev Genet. 2019;20(2):89–108.

    Article  CAS  PubMed  Google Scholar 

  11. Ross RJ, Weiner MM, Lin H. PIWI proteins and PIWI-interacting RNAs in the soma. Nature. 2014;505(7483):353–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lin J, Zhou Y, Gu W. el piRNA regulates PIWIL1 to modulate the behavior of placental trophoblast cells and participates in preeclampsia. Oxid Med Cell Longev. 2022;2022:7856290.

    Article  PubMed  PubMed Central  Google Scholar 

  13. He J, Chen M, Xu J, Fang J, Liu Z, Qi H. Identification and characterization of Piwi-interacting RNAs in human placentas of preeclampsia. Sci Rep. 2021;11(1):15766.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Han BW, Zamore PD. piRNAs. Curr Biol. 2014;24(16):R730–3.

    Article  CAS  PubMed  Google Scholar 

  15. Girard A, Sachidanandam R, Hannon GJ, Carmell MA. A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature. 2006;442(7099):199–202.

    Article  PubMed  Google Scholar 

  16. Honda S, Kawamura T, Loher P, Morichika K, Rigoutsos I, Kirino Y. The biogenesis pathway of tRNA-derived piRNAs in Bombyx germ cells. Nucleic Acids Res. 2017;45(15):9108–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zhong F, Zhou N, Wu K, Guo Y, Tan W, Zhang H, et al. A SnoRNA-derived piRNA interacts with human interleukin-4 pre-mRNA and induces its decay in nuclear exosomes. Nucleic Acids Res. 2015;43(21):10474–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Pippadpally S, Venkatesh T. iphering piRNA biogenesis through cytoplasmic granules, mitochondria and exosomes. Arch Biochem Biophys. 2020;695:108597.

    Article  CAS  PubMed  Google Scholar 

  19. Izumi N, Shoji K, Suzuki Y, Katsuma S, Tomari Y. Zucchini consensus motifs determine the mechanism of pre-piRNA production. Nature. 2020;578(7794):311–6.

    Article  CAS  PubMed  Google Scholar 

  20. Ipsaro JJ, Haase AD, Knott SR, Joshua-Tor L, Hannon GJ. The structural biochemistry of Zucchini implicates it as a nuclease in piRNA biogenesis. Nature. 2012;491(7423):279–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sienski G, Dönertas D, Brennecke J. Transcriptional silencing of transposons by Piwi and maelstrom and its impact on chromatin state and gene expression. Cell. 2012;151(5):964–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Huang X, Wong G. An old weapon with a new function: PIWI-interacting RNAs in neurodegenerative diseases. Transl Neurodegener. 2021;10(1):9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lin H. piRNAs in the germ line. Science. 2007;316(5823):397.

    Article  CAS  PubMed  Google Scholar 

  24. Czech B, Hannon GJ. One loop to rule them all: the ping-pong cycle and piRNA-guided silencing. Trends Biochem Sci. 2016;41(4):324–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sato K, Siomi MC. The piRNA pathway in Drosophila ovarian germ and somatic cells. Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(1):32–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhang Q, Zhu Y, Cao X, Tan W, Yu J, Lu Y, et al. The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers. Mol Cancer. 2023;22(1):45.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Jia DD, Jiang H, Zhang YF, Zhang Y, Qian LL, Zhang YF. The regulatory function of piRNA/PIWI complex in cancer and other human diseases: The role of DNA methylation. Int J Biol Sci. 2022;18(8):3358–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ernst C, Odom DT, Kutter C. The emergence of piRNAs against transposon invasion to preserve mammalian genome integrity. Nat Commun. 2017;8(1):1411.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Luo S, Zhang H, Duan Y, Yao X, Clark AG, Lu J. The evolutionary arms race between transposable elements and piRNAs in Drosophila melanogaster. BMC Evol Biol. 2020;20(1):14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Cornes E, Bourdon L, Singh M, Mueller F, Quarato P, Wernersson E, et al. piRNAs initiate transcriptional silencing of spermatogenic genes during C. elegans germline development. Dev Cell. 2022;57(2):180-96.e7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mei Y, Wang Y, Kumari P, Shetty AC, Clark D, Gable T, et al. A piRNA-like small RNA interacts with and modulates p-ERM proteins in human somatic cells. Nat Commun. 2015;6:7316.

    Article  CAS  PubMed  Google Scholar 

  32. Yao Y, Li Y, Zhu X, Zhao C, Yang L, Huang X, et al. The emerging role of the piRNA/PIWI complex in respiratory tract diseases. Respir Res. 2023;24(1):76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Liu Y, Cheng X, Li H, Hui S, Zhang Z, Xiao Y, et al. Non-coding RNAs as novel regulators of neuroinflammation in alzheimer’s disease. Front Immunol. 2022;13:908076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Zeng Q, Cai J, Wan H, Zhao S, Tan Y, Zhang C, et al. PIWI-interacting RNAs and PIWI proteins in diabetes and cardiovascular disease: Molecular pathogenesis and role as biomarkers. Clin Chim Acta. 2021;518:33–7.

    Article  CAS  PubMed  Google Scholar 

  35. Zhou Y, Fang Y, Dai C, Wang Y. PiRNA pathway in the cardiovascular system: a novel regulator of cardiac differentiation, repair and regeneration. J Mol Med (Berl). 2021;99(12):1681–90.

    Article  CAS  PubMed  Google Scholar 

  36. Wu X, Pan Y, Fang Y, Zhang J, Xie M, Yang F, et al. The biogenesis and functions of piRNAs in human diseases. Mol Ther Nucleic Acids. 2020;21:108–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Fathizadeh H, Asemi Z. Epigenetic roles of PIWI proteins and piRNAs in lung cancer. Cell Biosci. 2019;9:102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Onishi R, Yamanaka S, Siomi MC. piRNA- and siRNA-mediated transcriptional repression in Drosophila, mice, and yeast: new insights and biodiversity. EMBO Rep. 2021;22(10):e53062.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Liu Y, Dou M, Song X, Dong Y, Liu S, Liu H, et al. The emerging role of the piRNA/piwi complex in cancer. Mol Cancer. 2019;18(1):123.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Priyadarshini M, Ni JZ, Vargas-Velazquez AM, Gu SG, Frøkjær-Jensen C. Reprogramming the piRNA pathway for multiplexed and transgenerational gene silencing in C. elegans. Nat Methods. 2022;19(2):187–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Montgomery BE, Vijayasarathy T, Marks TN, Cialek CA, Reed KJ, Montgomery TA. Dual roles for piRNAs in promoting and preventing gene silencing in C. elegans. Cell Rep. 2021;37(10):110101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wang C, Lin H. Roles of piRNAs in transposon and pseudogene regulation of germline mRNAs and lncRNAs. Genome Biol. 2021;22(1):27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Zhang L, Meng X, Li D, Han X. piR-001773 and piR-017184 promote prostate cancer progression by interacting with PCDH9. Cell Signal. 2020;76:109780.

    Article  CAS  PubMed  Google Scholar 

  44. Sarkar A, Volff JN, Vaury C. piRNAs and their diverse roles: a transposable element-driven tactic for gene regulation? Faseb j. 2017;31(2):436–46.

    Article  CAS  PubMed  Google Scholar 

  45. Tan L, Mai D, Zhang B, Jiang X, Zhang J, Bai R, et al. PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer. 2019;18(1):9.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Wang K, Zhou LY, Liu F, Lin L, Ju J, Tian PC, et al. PIWI-Interacting RNA HAAPIR Regulates Cardiomyocyte Death After Myocardial Infarction by Promoting NAT10-Mediated ac(4) C Acetylation of Tfec mRNA. Adv Sci (Weinh). 2022;9(8):e2106058.

    Article  PubMed  Google Scholar 

  47. Mai D, Ding P, Tan L, Zhang J, Pan Z, Bai R, et al. PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics. 2018;8(19):5213–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Chen M, Chao B, Xu J, Liu Z, Tao Y, He J, et al. CPT1A modulates PI3K/Akt/mTOR pathway to promote preeclampsia. Placenta. 2023;133:23–31.

    Article  PubMed  Google Scholar 

  49. Liu M, Liao L, Gao Y, Yin Y, Wei X, Xu Q, et al. BCAM Deficiency May Contribute to Preeclampsia by Suppressing the PIK3R6/p-STAT3 Signaling. Hypertension. 2022;79(12):2830–42.

    Article  CAS  PubMed  Google Scholar 

  50. Ernst LM. Maternal vascular malperfusion of the placental bed. APMIS. 2018;126(7):551–60.

    Article  PubMed  Google Scholar 

  51. Staff AC, Fjeldstad HE, Fosheim IK, Moe K, Turowski G, Johnsen GM, et al. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. Am J Obstet Gynecol. 2022;226(2s):S895-s906.

    Article  CAS  PubMed  Google Scholar 

  52. Apicella C, Ruano CSM, Méhats C, Miralles F, Vaiman D. The role of epigenetics in placental development and the etiology of preeclampsia. Int J Mol Sci. 2019;20(11):2837.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ashraf UM, Hall DL, Rawls AZ, Alexander BT. Epigenetic processes during preeclampsia and effects on fetal development and chronic health. Clin Sci (Lond). 2021;135(19):2307–27.

    Article  CAS  PubMed  Google Scholar 

  54. Zeng Y, Wei L, Lali MS, Chen Y, Yu J, Feng L. miR-150-5p mediates extravillous trophoblast cell migration and angiogenesis functions by regulating VEGF and MMP9. Placenta. 2020;93:94–100.

    Article  CAS  PubMed  Google Scholar 

  55. Huang Y, Zhang Y, Zhang L. Expression levels of serum mir-145–5p and Gas6 in women with early-onset preeclampsia and their clinical significance. Cell Mol Biol (Noisy-le-grand). 2022;68(1):209–16.

    Article  PubMed  Google Scholar 

  56. Zhang Q, Wang Z, Cheng X, Wu H. lncRNA DANCR promotes the migration an invasion and of trophoblast cells through microRNA-214-5p in preeclampsia. Bioengineered. 2021;12(2):9424–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Zhao X, Su F, Guo Q, Tao X, Wang H, Wang H, et al. Preeclampsia-associated lncRNA FEZF1-AS1 regulates cell proliferation and apoptosis in placental trophoblast cells through the ELAVL1/NOC2L axis. Cell Div. 2023;18(1):17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Lip SV, Boekschoten MV, Hooiveld GJ, van Pampus MG, Scherjon SA, Plösch T, et al. Early-onset preeclampsia, plasma microRNAs, and endothelial cell function. Am J Obstet Gynecol. 2020;222(5):497.e1-.e12.

    Article  CAS  PubMed  Google Scholar 

  59. Martinez VD, Sage AP, Minatel BC, Marshall EA, Price EM, Becker-Santos DD, et al. Human placental piwi-interacting RNA transcriptome is characterized by expression from the DLK1-DIO3 imprinted region. Sci Rep. 2021;11(1):14981.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Acosta-Martinez M, Cabail MZ. The PI3K/Akt pathway in meta-inflammation. Int J Mol Sci. 2022;23(23):15330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Khezri MR, Jafari R, Yousefi K, Zolbanin NM. The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. Exp Mol Pathol. 2022;127:104787.

    Article  CAS  PubMed  Google Scholar 

  62. Xue C, Li G, Lu J, Li L. Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression. Signal Transduct Target Ther. 2021;6(1):400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Sun K, Luo J, Guo J, Yao X, Jing X, Guo F. The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthritis Cartilage. 2020;28(4):400–9.

    Article  CAS  PubMed  Google Scholar 

  64. Sharma A, Mehan S. Targeting PI3K-AKT/mTOR signaling in the prevention of autism. Neurochem Int. 2021;147:105067.

    Article  CAS  PubMed  Google Scholar 

  65. Fakhri S, Iranpanah A, Gravandi MM, Moradi SZ, Ranjbari M, Majnooni MB, et al. Natural products attenuate PI3K/Akt/mTOR signaling pathway: A promising strategy in regulating neurodegeneration. Phytomedicine. 2021;91:153664.

    Article  CAS  PubMed  Google Scholar 

  66. Huang J, Chen L, Wu J, Ai D, Zhang JQ, Chen TG, et al. Targeting the PI3K/AKT/mTOR signaling pathway in the treatment of human diseases: current status, trends, and solutions. J Med Chem. 2022;65(24):16033–61.

    Article  CAS  PubMed  Google Scholar 

  67. Deng CY, Lv M, Luo BH, Zhao SZ, Mo ZC, Xie YJ. The role of the PI3K/AKT/mTOR signalling pathway in male reproduction. Curr Mol Med. 2021;21(7):539–48.

    CAS  PubMed  Google Scholar 

  68. Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. 2022;12:819128.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):4507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019;59:147–60.

    Article  CAS  PubMed  Google Scholar 

  71. Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612–32.

    PubMed  Google Scholar 

  72. Nepstad I, Hatfield KJ, Grønningsæter IS, Reikvam H. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) Cells. Int J Mol Sci. 2020;21(8):2907.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treat Rev. 2019;72:45–55.

    Article  CAS  PubMed  Google Scholar 

  74. Wang L, Zhang Y, Qu H, Xu F, Hu H, Zhang Q, et al. Reduced ELABELA expression attenuates trophoblast invasion through the PI3K/AKT/mTOR pathway in early onset preeclampsia. Placenta. 2019;87:38–45.

    Article  CAS  PubMed  Google Scholar 

  75. Li Y, Sun XL, Ma CL, Li C, Zhan Y, Li WT, et al. STX2 promotes trophoblast growth, migration, and invasion through activation of the PI3K-AKT pathway in Preeclampsia. Front Cell Dev Biol. 2021;9:615973.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Chen J, Yue C, Xu J, Zhan Y, Zhao H, Li Y, et al. Downregulation of receptor tyrosine kinase-like orphan receptor 1 in preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion by PI3K/AKT/mTOR pathway accommodation. Placenta. 2019;82:17–24.

    Article  CAS  PubMed  Google Scholar 

  77. Shen H, Jin M, Gu S, Wu Y, Yang M, Hua X. CD97 is decreased in preeclamptic placentas and promotes human trophoblast invasion through PI3K/Akt/mTOR signaling pathway. Reprod Sci. 2020;27(8):1553–61.

    Article  PubMed  Google Scholar 

  78. Dai H, Lu X. MGST1 alleviates the oxidative stress of trophoblast cells induced by hypoxia/reoxygenation and promotes cell proliferation, migration, and invasion by activating the PI3K/AKT/mTOR pathway. Open Med (Wars). 2022;17(1):2062–71.

    Article  CAS  PubMed  Google Scholar 

  79. Shen H, Jin M, Gu S, Wu Y, Yang M, Hua X. CD97 Is decreased in preeclamptic placentas and promotes human trophoblast invasion through PI3K/Akt/mTOR signaling pathway. Reprod Sci. 2019:1933719119828067.

  80. Peng L, Song L, Liu C, Lv X, Li X, Jie J, et al. piR-55490 inhibits the growth of lung carcinoma by suppressing mTOR signaling. Tumour Biol. 2016;37(2):2749–56.

    Article  CAS  PubMed  Google Scholar 

  81. Bao D, Zhuang C, Jiao Y, Yang L. The possible involvement of circRNA DMNT1/p53/JAK/STAT in gestational diabetes mellitus and preeclampsia. Cell Death Discov. 2022;8(1):121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Mo HQ, Tian FJ, Ma XL, Zhang YC, Zhang CX, Zeng WH, et al. PDIA3 regulates trophoblast apoptosis and proliferation in preeclampsia via the MDM2/p53 pathway. Reproduction. 2020;160(2):293–305.

    Article  CAS  PubMed  Google Scholar 

  83. Lee S, Jung Park M, Joo Lee H, Kil Joo J, Soo Suh D, Un Choi K, et al. Decreased expression of caveolin-1 have relevance to promoted senescence in preeclamptic placenta. Pregnancy Hypert. 2022;30:59–67.

    Article  Google Scholar 

  84. Zhao Y, Zhao G, Li W. MicroRNA-495 suppresses pre-eclampsia via activation of p53/PUMA axis. Cell Death Discov. 2022;8(1):132.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Li D, Ge Y, Zhao Z, Zhu R, Wang X, Bi X. Distinct and coordinated regulation of small non-coding RNAs by E2f1 and p53 during drosophila development and in response to DNA damage. Front Cell Dev Biol. 2021;9:695311.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Mi T, Tan X, Wang Z, Zhang Z, Jin L, Wang J, et al. Activation of the p53 signaling pathway by piRNA-MW557525 overexpression induces a G0/G1 phase arrest thus inhibiting neuroblastoma growth. Eur J Med Res. 2023;28(1):503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Liao L, Liu M, Gao Y, Wei X, Yin Y, Gao L, et al. The long noncoding RNA TARID regulates the CXCL3/ERK/MAPK pathway in trophoblasts and is associated with preeclampsia. Reprod Biol Endocrinol. 2022;20(1):159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Ding L, Li S, Zhang Y, Gai J, Kou J. MXRA5 is decreased in preeclampsia and affects trophoblast cell invasion through the MAPK pathway. Mol Cell Endocrinol. 2018;461:248–55.

    Article  CAS  PubMed  Google Scholar 

  89. Liu M, Wang RB, Xing JH, Tang YX. Atractylenolide inhibits apoptosis and oxidative stress of HTR-8/SVneo cells by activating MAPK/ERK signalling in preeclampsia. Phytomedicine. 2021;93:153773.

    Article  CAS  PubMed  Google Scholar 

  90. Dietrich B, Haider S, Meinhardt G, Pollheimer J, Knöfler M. WNT and NOTCH signaling in human trophoblast development and differentiation. Cell Mol Life Sci. 2022;79(6):292.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Zhang Y, Ran Y, Ma Y, Huang H, Chen Y, Qi H. Elevated serum SFRP5 levels during preeclampsia and its potential association with trophoblast dysfunction via Wnt/β-catenin suppression. Reprod Sci. 2022;29(1):163–72.

    Article  CAS  PubMed  Google Scholar 

  92. Li N, Huang L, Li Y, Chen X, Yang Y, Hou Y, et al. Lin28B/miR-92b promote the proliferation, migration, and invasion in the pathogenesis of preeclampsia via the DKK1/Wnt/β-catenin pathway. Reprod Sci. 2020;27(3):815–22.

    Article  CAS  PubMed  Google Scholar 

  93. Nikolov A, Popovski N. Role of gelatinases MMP-2 and MMP-9 in healthy and complicated pregnancy and their future potential as preeclampsia biomarkers. Diagnostics (Basel). 2021;11(3):480.

    Article  CAS  PubMed  Google Scholar 

  94. Timokhina E, Strizhakov A, Ibragimova S, Gitel E, Ignatko I, Belousova V, et al. Matrix metalloproteinases MMP-2 and MMP-9 occupy a new role in severe preeclampsia. J Pregnancy. 2020;2020:8369645.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Li W, Gonzalez-Gonzalez M, Sanz-Criado L, Garcia-Carbonero N, Celdran A, Villarejo-Campos P, et al. A Novel PiRNA Enhances CA19-9 sensitivity for pancreatic cancer identification by liquid biopsy. J Clin Med. 2022;11(24):7310.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Huang Y, Li Y, Zhang K, Xu J, Li P, Yan X, et al. Expression and diagnostic value of PIWI-interacting RNA by serum in acute myocardial infarction. J Cardiol. 2023;82(6):441–7.

    Article  PubMed  Google Scholar 

  97. Peng Q, Chiu PK, Wong CY, Cheng CK, Teoh JY, Ng CF. Identification of piRNA targets in urinary extracellular vesicles for the diagnosis of prostate cancer. Diagnostics (Basel). 2021;11(10):1828.

    Article  CAS  PubMed  Google Scholar 

  98. Chen G, Wang S, Long C, Wang Z, Chen X, Tang W, et al. PiRNA-63049 inhibits bone formation through Wnt/β-catenin signaling pathway. Int J Biol Sci. 2021;17(15):4409–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Qi T, Cao H, Sun H, Feng H, Li N, Wang C, et al. piR-19166 inhibits migration and metastasis through CTTN/MMPs pathway in prostate carcinoma. Aging (Albany NY). 2020;12(18):18209–20.

    Article  CAS  PubMed  Google Scholar 

  100. Tomimatsu T, Mimura K, Matsuzaki S, Endo M, Kumasawa K, Kimura T. Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors. Int J Mol Sci. 2019;20(17):4246.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Lipps C, Northe P, Figueiredo R, Rohde M, Brahmer A, Krämer-Albers EM, et al. Non-invasive approach for evaluation of pulmonary hypertension using extracellular vesicle-associated small non-coding RNA. Biomolecules. 2019;9(11):666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Li M, Yang Y, Wang Z, Zong T, Fu X, Aung LHH, et al. Piwi-interacting RNAs (piRNAs) as potential biomarkers and therapeutic targets for cardiovascular diseases. Angiogenesis. 2021;24(1):19–34.

    Article  CAS  PubMed  Google Scholar 

  103. Suvakov S, Bonner E, Nikolic V, Jerotic D, Simic TP, Garovic VD, et al. Overlapping pathogenic signalling pathways and biomarkers in preeclampsia and cardiovascular disease. Pregnancy Hypertens. 2020;20:131–6.

    Article  PubMed  Google Scholar 

  104. Albogami SM, Al-Kuraishy HM, Al-Maiahy TJ, Al-Buhadily AK, Al-Gareeb AI, Alorabi M, et al. Hypoxia-Inducible Factor 1 and Preeclampsia: A New Perspective. Curr Hypertens Rep. 2022;24(12):687–92.

    Article  CAS  PubMed  Google Scholar 

  105. Feng J, Yang M, Wei Q, Song F, Zhang Y, Wang X, et al. el evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer. J Cell Mol Med. 2020;24(16):9028–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Aggarwal R, Jain AK, Mittal P, Kohli M, Jawanjal P, Rath G. Association of pro- and anti-inflammatory cytokines in preeclampsia. J Clin Lab Anal. 2019;33(4):e22834.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Cooley A, Rayford KJ, Arun A, Villalta F, Lima MF, Pratap S, et al. Trypanosoma cruzi dysregulates piRNAs computationally predicted to target IL-6 signaling molecules during early infection of primary human cardiac fibroblasts. Immune Netw. 2022;22(6):e51.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Taysi S, Tascan AS, Ugur MG, Demir M. Radicals, oxidative/nitrosative stress and preeclampsia. Mini Rev Med Chem. 2019;19(3):178–93.

    Article  CAS  PubMed  Google Scholar 

  109. Olufunmilayo EO, Holsinger RMD. Roles of non-coding RNA in Alzheimer’s disease pathophysiology. Int J Mol Sci. 2023;24(15):12498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Zhang L, Meng X, Pan C, Qu F, Gan W, Xiang Z, et al. piR-31470 epigenetically suppresses the expression of glutathione S-transferase pi 1 in prostate cancer via DNA methylation. Cell Signal. 2020;67:109501.

    Article  CAS  PubMed  Google Scholar 

  111. Du X, Li H, Xie X, Shi L, Wu F, Li G, et al. piRNA-31115 promotes cell proliferation and invasion via PI3K/AKT pathway in clear cell renal carcinoma. Dis Markers. 2021;2021:6915329.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Ma H, Wang H, Tian F, Zhong Y, Liu Z, Liao A. PIWI-Interacting RNA-004800 is regulated by S1P receptor signaling pathway to keep myeloma cell survival. Front Oncol. 2020;10: 438.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Natenzon A, McFadden P, DaSilva-Arnold SC, Zamudio S, Illsley NP. Diminished trophoblast differentiation in early onset preeclampsia. Placenta. 2022;120:25–31.

    Article  PubMed  Google Scholar 

  114. Wu D, Shi L, Chen X, Cen H, Mao D. β-TrCP suppresses the migration and invasion of trophoblast cells in preeclampsia by down-regulating Snail. Exp Cell Res. 2020;395(2):112230.

    Article  CAS  PubMed  Google Scholar 

  115. Li G, Yi X, Du S, Gong L, Wu Q, Cai J, et al. Tumour-derived exosomal piR-25783 promotes omental metastasis of ovarian carcinoma by inducing the fibroblast to myofibroblast transition. Oncogene. 2023;42(6):421–33.

    Article  CAS  PubMed  Google Scholar 

  116. Tang X, Xie X, Wang X, Wang Y, Jiang X, Jiang H. The combination of piR-823 and eukaryotic initiation factor 3 B (EIF3B) activates hepatic stellate cells via upregulating TGF-β1 in liver fibrogenesis. Med Sci Monit. 2018;24:9151–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Tanaka M, Inaba Y, Yariyama A, Nakatani Y, Kunimoto K, Kaminaka C, et al. Expression of collagen-related piRNA is dysregulated in cultured dermal fibroblasts derived from patients with scleroderma. Intractable Rare Dis Res. 2023;12(4):241–5.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Ding X, Li Y, Lü J, Zhao Q, Guo Y, Lu Z, et al. piRNA-823 Is Involved in Cancer Stem Cell Regulation Through Altering DNA Methylation in Association With Luminal Breast Cancer. Front Cell Dev Biol. 2021;9:641052.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Das B, Jain N, Mallick B. piR-39980 promotes cell proliferation, migration and invasion, and inhibits apoptosis via repression of SERPINB1 in human osteosarcoma. Biol Cell. 2020;112(3):73–91.

    Article  CAS  PubMed  Google Scholar 

  120. Dymara-Konopka W, Laskowska M, Błażewicz A. Angiogenic imbalance as a contributor of preeclampsia. Curr Pharm Biotechnol. 2018;19(10):797–815.

    Article  CAS  PubMed  Google Scholar 

  121. Li B, Hong J, Hong M, Wang Y, Yu T, Zang S, et al. piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 2019;38(26):5227–38.

    Article  CAS  PubMed  Google Scholar 

  122. Ren JS, Bai W, Ding JJ, Zhao Y, Wang SY, Chen X, et al. The role of PIWIL4 and piRNAs in the development of choroidal neovascularization. Genomics. 2023;115(3):110615.

    Article  CAS  PubMed  Google Scholar 

  123. Sivagurunathan S, Raman R, Chidambaram S. PIWI-like protein, HIWI2: A novel player in proliferative diabetic retinopathy. Exp Eye Res. 2018;177:191–6.

    Article  CAS  PubMed  Google Scholar 

  124. Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol. 2018;81:241–330.

    Article  CAS  PubMed  Google Scholar 

  125. Zhong N, Nong X, Diao J, Yang G. piRNA-6426 increases DNMT3B-mediated SOAT1 methylation and improves heart failure. Aging (Albany NY). 2022;14(6):2678–94.

    Article  CAS  PubMed  Google Scholar 

  126. Chu C, Yu L, Henry-Berger J, Ru YF, Kocer A, Champroux A, et al. Knockout of glutathione peroxidase 5 down-regulates the piRNAs in the caput epididymidis of aged mice. Asian J Androl. 2020;22(6):590–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Qu A, Wang W, Yang Y, Zhang X, Dong Y, Zheng G, et al. A serum piRNA signature as promising non-invasive diagnostic and prognostic biomarkers for colorectal cancer. Cancer Manag Res. 2019;11:3703–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Mai D, Zheng Y, Guo H, Ding P, Bai R, Li M, et al. Serum piRNA-54265 is a new biomarker for early detection and clinical surveillance of human colorectal cancer. Theranostics. 2020;10(19):8468–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Gál L, Fóthi Á, Orosz G, Nagy S, Than NG, Orbán TI. Exosomal small RNA profiling in first-trimester maternal blood explores early molecular pathways of preterm preeclampsia. Front Immunol. 2024;15:1321191.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Chen S, Ben S, Xin J, Li S, Zheng R, Wang H, et al. The biogenesis and biological function of PIWI-interacting RNA in cancer. J Hematol Oncol. 2021;14(1):93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Riffo-Campos AL, Perez-Hernandez J, Ortega A, Martinez-Arroyo O, Flores-Chova A, Redon J, et al. Exosomal and plasma non-coding RNA signature associated with urinary albumin excretion in hypertension. Int J Mol Sci. 2022;23(2):823.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Das B, Roy J, Jain N, Mallick B. Tumor suppressive activity of PIWI-interacting RNA in human fibrosarcoma mediated through repression of RRM2. Mol Carcinog. 2019;58(3):344–57.

    Article  CAS  PubMed  Google Scholar 

  133. Ma C, Zhang L, Wang X, He S, Bai J, Li Q, et al. piRNA-63076 contributes to pulmonary arterial smooth muscle cell proliferation through acyl-CoA dehydrogenase. J Cell Mol Med. 2020;24(9):5260–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Liu T, Wang J, Sun L, Li M, He X, Jiang J, et al. Piwi-interacting RNA-651 promotes cell proliferation and migration and inhibits apoptosis in breast cancer by facilitating DNMT1-mediated PTEN promoter methylation. Cell Cycle. 2021;20(16):1603–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Editage (www.editage.cn) for English language editing.

Funding

This work was supported by Natural Science Fund Project of Shandong Province [ZR2019MH127].

Author information

Authors and Affiliations

  1. Prenatal Diagnosis Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, Shandong, China

    Yuanxuan Ma & Shiguo Liu

  2. Department of Medical Genetics, the Affiliated Hospital of Qingdao University, Qingdao , Shandong, 266003, China

    Yuanxuan Ma & Shiguo Liu

  3. Department of Cardiology, the Affiliated Hospital of Qingdao University, Qingdao , Shandong, 266003, China

    Bo Hou

  4. Department of Laboratory, Qingdao Hiser Hospital Affliated of Qingdao University (Oingdao Traditional Chinese Medicine Hospital), 4 Renmin Road, Qingdao, 266033, China

    Jinbao Zong

  5. Medical Genetic Department, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, China

    Shiguo Liu

Authors
  1. Yuanxuan Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bo Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinbao Zong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shiguo Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Ma and Hou contributed to data collection and article writing. Liu and Zong designed the study and reviewed draft. All authors contributed to the article and approved the submitted version.

Corresponding authors

Correspondence to Jinbao Zong or Shiguo Liu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, Y., Hou, B., Zong, J. et al. Potential molecular mechanisms and clinical implications of piRNAs in preeclampsia: a review. Reprod Biol Endocrinol 22, 73 (2024). https://doi.org/10.1186/s12958-024-01247-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12958-024-01247-1

Keywords

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us